Navigation Links
Reportlinker Adds Key Companies: HIV - Companies Co-Operate and Co-Formulate to Stay Competitive in a Tight HIV Market

NEW YORK, June 27, 2011 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Key Companies: HIV - Companies co-operate and co-formulate to stay competitive in a tight HIV market


HIV across the seven major markets is largely dominated by two companies: Gilead Sciences and ViiV Healthcare. The growing dominance of convenient one-pill once-daily regimens will increasingly pressure companies to collaborate and co-formulate their marketed and/or pipeline HIV drugs into fixed dose combinations (FDCs) to remain successful in a tight HIV market.

Features and benefits

* In-depth discussion of portfolios and strategies of key HIV companies.

* Discussion of future strategic opportunities to achieve success in a crowded HIV market.

* Review of corporate strategies in HIV.


With Gilead and ViiV Healthcare clearly dominating the HIV market, the remaining companies active in the field have much smaller HIV portfolios. An emerging HIV treatment trend towards nuc-sparing regimens offers opportunities for smaller players to form new vertical collaborations and to diversify the HIV field.

With its blockbuster products Truvada (tenofovir disoproxil fumarate/emtricitabine) and Atripla (tenofovir disoproxil fumarate/emtricitabine/efavirenz), Gilead Sciences is the current HIV market leader in the seven major markets. Its strong late-stage pipeline will help Gilead to defend this position in the short- to mid-term future.

ViiV Healthcare's currently marketed HIV portfolio is diverse but includes several older drugs. However, of all companies involved in the HIV field, ViiV has by far the richest and most diverse HIV pipeline, offering plenty of opportunity to challenge Gilead's current position as HIV market leader in the mid-to long-term future.

Your key questions answered

* Learn about the key HIV companies active in the seven major markets and their portfolios of marketed and pipeline HIV drugs.

* Recognize trends in HIV drug development and learn how companies can respond to future opportunities and challenges in the field.

* Understand corporate strategies for the life-cycle management of HIV drugs in the seven major markets.

Executive Summary

Strategic scoping and focus

Datamonitor key findings

Related reports





Strategic overview

Trends in corporate strategy

Co-operating and co-formulating are the key strategies to claim HIV market share

Nuc-sparing regimens could diversify the HIV field

Greater choice among different HIV regimens could pave the way towards individualized treatment

Smaller companies are betting on novel delivery methods and other innovative approaches for HIV treatment

Recent strategic partnerships/deals

Gilead Sciences/Bristol-Myers Squibb's joint venture for Atripla kick-started a new era in HIV development

In 2009, GlaxoSmithKline and Pfizer formed specialist HIV company ViiV Healthcare

GlaxoSmithKline/ViiV team up with Shionogi to gain competitive edge in HIV

Gilead and Tibotec/Johnson & Johnson join forces to develop Truvada/rilpivirine

Merck & Co. and Schering-Plough merge but HIV portfolio faces major challenges


Corporate strategy

The success of Truvada and Atripla is the foundation of Gilead's leadership in the HIV market

Moving forward, Gilead's bet on FDCs will cement the company's position as HIV market leader in the short- to mid-term future

HIV portfolio assessment

SWOT analysis for Gilead's HIV portfolio


Corporate strategy

ViiV sets out to challenge Gilead's market dominance

HIV portfolio assessment

SWOT analysis for ViiV Healthcare's HIV portfolio


Companies are looking to the market leaders to co-formulate their novel HIV candidates

Tibotec/Johnson & Johnson: US approval of Edurant further strengthens position in the HIV market

Bristol-Myers Squibb: Sustiva's patent expiry and a slim HIV pipeline will weaken HIV franchise

Merck & Co: setbacks in 2010 threaten competitiveness in the HIV market

Abbott: HIV position set to decline following Norvir's patent expiry in 2013/2014

Boehringer Ingelheim: strong reliance on Viramune and Aptivus as key setback for future growth in HIV

Roche: suspended HIV research in 2008


Journal papers


Datamonitor reports


Contributing experts

Conferences attended

Report methodology

To order this report:

Pathology Industry: Key Companies: HIV - Companies co-operate and co-formulate to stay competitive in a tight HIV market

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds The Outlook for Medical Devices in Brazil, Russia, India & China
2. Reportlinker Adds North America Acetic Acid Industry Outlook to 2015 - Market Size, Company Share, Price Trends, Capacity Forecasts of All Active and Planned Plants
3. Reportlinker Adds U.S. Urinary Incontinence Devices
4. Reportlinker Adds U.S. Retinal Therapeutics Market
5. Reportlinker Adds Global CRO Market: Quantitative Assessment
6. Reportlinker Adds The Outlook for Medical Devices in North East Asia
7. Reportlinker Adds Global Microbiology Testing Market: US, Europe, Japan--Emerging Opportunities and Business Expansion Strategies for Suppliers
8. Reportlinker Adds Endovascular Surgical Interventions: Technology Market Penetration and Roadmapping
9. Reportlinker Adds Global Hemostasis Diagnostics Market: US, Europe, Japan--Emerging Opportunities and Business Expansion Strategies for Suppliers
10. Reportlinker Adds Global Nucleic Acid Testing Market--New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers
11. Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers
Post Your Comments:
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... Nueva York , 24 de noviembre de ... del Avery Breathing Pacemaker System, se complace anunciar ... Ph.D. como consultor clínico. ... Foto -   ... Jonzon es un fisiólogo y consultor en neonatología ...
(Date:11/24/2015)... --> --> ... by Product Type (Bone Graft, Bine Graft Substitute, Platelet Rich ... Lumbar Interbody Fusion), End User, and Geography - Global Forecast ... at $1.90 Billion in 2014 and is expected to reach ... the forecast period of 2015 to 2020. Browse ...
Breaking Medicine Technology:
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... According ... Vinci surgical robot is being more and more widely heralded as a breakthrough for ... da Vinci method has over traditional laparoscopic surgery is that it can greatly reduce ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm ... appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto ... Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock testified ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw ... and learning in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. ... For 65 years, Brillianteen has been a treasured tradition for numerous families in ...
(Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a non-profit organization devoted ... as raising public awareness of the disorder while helping to bring expert medical ... $35,000 to bolster progress at the Tuberous Sclerosis Complex Center at Ann & ...
Breaking Medicine News(10 mins):